The Clinical Value of Measuring Circulating HPV DNA during Chemo-Radiotherapy in Squamous Cell Carcinoma of the Anus.
anus neoplasms
circulating tumor DNA
human papillomavirus
squamous cell carcinoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 May 2021
18 May 2021
Historique:
received:
06
04
2021
revised:
07
05
2021
accepted:
14
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Circulating tumor DNA (ctDNA) is investigated in various cancers. In squamous cell carcinoma of the anus (SCCA) infection with human papilloma virus (HPV) is found in around 90% of cases and here, plasma HPV (pHPV) can be used as ctDNA. Preliminary data have proved the ability to detect pHPV16 and -18 in SCCA. We have developed a highly sensitive method for measurement of six relevant pHPV subtypes, to investigate the elimination pattern of pHPV during chemo-radiotherapy (CRT) for SCCA and its clinical value. Patients treated at Aarhus University Hospital from 2016-2020 were included. P16 status in the primary biopsy was measured and 82% of patients had P16 positive tumor. Blood samples were collected prior to treatment (PT), mid treatment (MT), end of therapy (EOT), and during follow-up (FU). An in-house multiplex digital droplet PCR method measured pHPV subtypes 16, 18, 31, 33, 51, 58. Samples from 88 patients were drawn PT ( During CRT, pHPV can divide patients with SCCA into three groups with significantly different risk of failure. The use of pHPV can potentially assist in clinical treatment decision.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Circulating tumor DNA (ctDNA) is investigated in various cancers. In squamous cell carcinoma of the anus (SCCA) infection with human papilloma virus (HPV) is found in around 90% of cases and here, plasma HPV (pHPV) can be used as ctDNA. Preliminary data have proved the ability to detect pHPV16 and -18 in SCCA. We have developed a highly sensitive method for measurement of six relevant pHPV subtypes, to investigate the elimination pattern of pHPV during chemo-radiotherapy (CRT) for SCCA and its clinical value.
MATERIAL AND METHODS
METHODS
Patients treated at Aarhus University Hospital from 2016-2020 were included. P16 status in the primary biopsy was measured and 82% of patients had P16 positive tumor. Blood samples were collected prior to treatment (PT), mid treatment (MT), end of therapy (EOT), and during follow-up (FU). An in-house multiplex digital droplet PCR method measured pHPV subtypes 16, 18, 31, 33, 51, 58.
RESULTS
RESULTS
Samples from 88 patients were drawn PT (
CONCLUSION
CONCLUSIONS
During CRT, pHPV can divide patients with SCCA into three groups with significantly different risk of failure. The use of pHPV can potentially assist in clinical treatment decision.
Identifiants
pubmed: 34070045
pii: cancers13102451
doi: 10.3390/cancers13102451
pmc: PMC8158133
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Danish Comprehensive Cancer Center - Radiotherapy
Organisme : Kræftens Bekæmpelse
Organisme : Aarhus Universitetshospital
Organisme : Bio- and Genome Bank Denmark
Références
Oncotarget. 2017 Dec 21;9(8):8081-8088
pubmed: 29487716
Oncotarget. 2017 Dec 14;8(70):115230-115243
pubmed: 29383155
Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):329-339
pubmed: 31629837
Colorectal Dis. 2018 May;20(5):371-382
pubmed: 29566456
Clin Colorectal Cancer. 2019 Mar;18(1):e96-e103
pubmed: 30415990
Br J Cancer. 2017 Sep 5;117(6):876-883
pubmed: 28809864
Br J Cancer. 2014 Mar 18;110(6):1587-94
pubmed: 24518594
Acta Oncol. 2017 Jan;56(1):7-16
pubmed: 28010185
Radiother Oncol. 2018 Aug;128(2):375-379
pubmed: 29929860
Clin Cancer Res. 2018 Nov 15;24(22):5767-5771
pubmed: 30054279
Int J Cancer. 2011 Jul 15;129(2):433-9
pubmed: 20839262
J Clin Oncol. 2014 Jun 10;32(17):1812-7
pubmed: 24821878
Radiother Oncol. 2012 Nov;105(2):269-70
pubmed: 23127771
J Natl Cancer Inst. 2020 Aug 1;112(8):829-838
pubmed: 31742639
PLoS One. 2020 Mar 20;15(3):e0230622
pubmed: 32196518
Clin Cancer Res. 2019 Aug 1;25(15):4682-4690
pubmed: 31088830
Nat Rev Clin Oncol. 2020 Dec;17(12):757-770
pubmed: 32632268
Radiother Oncol. 2010 Jun;95(3):371-80
pubmed: 20493569
Clin Cancer Res. 2019 Apr 1;25(7):2109-2115
pubmed: 30504426
PLoS Pathog. 2017 Apr 6;13(4):e1006211
pubmed: 28384274
PLoS One. 2018 Feb 16;13(2):e0191581
pubmed: 29451891
Radiother Oncol. 2020 Sep;150:211-216
pubmed: 32622778
Colorectal Dis. 2015 Nov;17(11):O230-9
pubmed: 26218674
Ann Oncol. 2018 Sep 1;29(9):1980-1986
pubmed: 30010779
N Engl J Med. 2018 Nov 01;379(18):1754-1765
pubmed: 30380390
Cancer Cytopathol. 2019 Oct;127(10):632-642
pubmed: 31509355
Clin Chim Acta. 2015 Jun 15;446:141-6
pubmed: 25896958
JCO Precis Oncol. 2019;3:
pubmed: 31485558
Front Oncol. 2020 Apr 17;10:505
pubmed: 32363162
Am J Clin Pathol. 2009 Sep;132(3):378-90
pubmed: 19687314
J Pathol Clin Res. 2016 Jun 28;2(4):201-209
pubmed: 27917295
Hum Pathol. 2013 Jun;44(6):992-1002
pubmed: 23266444
Acta Oncol. 2020 Dec;59(12):1424-1429
pubmed: 32790489
Strahlenther Onkol. 2011 Mar;187(3):175-82
pubmed: 21347639
Neoplasia. 2013 Dec;15(12):1371-8
pubmed: 24403859
J Clin Oncol. 2020 Apr 1;38(10):1050-1058
pubmed: 32017652